The Potential to Optimize Clinical Trials Through Retinal Imaging: Sharon Cohen, MD, FRCPC
March 21st 2022The neurologist and assistant professor at the University of Toronto provided perspective on the multiple different ways retinal imaging can alter and improve the efficiency of research for Alzheimer disease. [WATCH TIME: 2 minutes]
Successes and Challenges in the New Era of Genetic Medicine: Nicholas E. Johnson, MD, MSci
March 20th 2022The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]
NeurologyLive® Brain Games: March 20, 2022
March 20th 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is optic neuritis and neuromyelitis optica spectrum disorder (NMOSD).
Zolgensma Reinforces Efficacy in SPR1NT Results of Patients With SMA and 3 Copies of SMN2
March 19th 2022The gene therapy from Novartis showed that it was both efficacious and well-tolerated in presymptomatic patients with SMA with 3 copies of SMN2, with no patients experiencing treatment-related serious adverse events.
Here Comes the Sun: AASM Backs Senate’s Decision to Abolish Daylight Saving Time
March 18th 2022The American Academy of Sleep Medicine has previously pointed to evidence showing that the sudden change from standard time to daylight saving time is associated with significant public health, safety risks, and circadian rhythm.
Validating and Expanding the Use of RetiSpec: Sharon Cohen, MD, FRCPC
March 18th 2022The neurologist and assistant professor at the University of Toronto commented on the next research efforts needed to further validate and demonstrate the diagnostic capabilities of RetiSpec. [WATCH TIME: 3 minutes]
Understanding the Newest Therapeutic Advances in Neuromuscular Diseases
March 17th 2022Jinsy Andrews, MD, MSc, FAAN, offered her perspective on the ongoing therapeutic boom in neuromuscular disease and some of the critical needs for physicians to keep up with a rapidly progressing treatment paradigm.
MDA 2022 Highlights the Therapeutic Advances for Neuromuscular Diseases: Donald S. Wood, PhD
March 17th 2022The president and CEO of the Muscular Dystrophy Association spoke about the highlights of this year’s annual meeting and the recent therapeutic advances for neuromuscular disorders. [WATCH TIME: 3 minutes]
Managing New Therapies for Neuromuscular Diseases: Jinsy Andrews, MD, MSc
March 16th 2022The director of neuromuscular clinical trials at Columbia University Irving Medical Center shared her perspective on the challenges of familiarizing oneself with the influx of novel medications for neuromuscular diseases. [WATCH TIME: 3 minutes]
The Revolution in Limb-Girdle Muscular Dystrophy With Gene Therapies: Nicholas E. Johnson, MD, MSci
March 16th 2022The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University offered his insight into the advances in genetic approaches to LGMD. [WATCH TIME: 2 minutes]
Assessing, Validating Clinically Relevant Biomarkers for Alzheimer Disease: Jefferson Kinney, PhD
March 15th 2022The founding chair of the department of brain health at the University of Nevada Las Vegas discussed the plethora of Alzheimer disease biomarkers and the need for consensus on the value of each. [WATCH TIME: 3 minutes]